Invesco Biotechnology & Genome ETF(PBE · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $62.63 – $85.73
- YTD
- +2.35%
- IV Rank (30D)
- 12.74
- Straddle Price
- $5.45
Invesco Biotechnology & Genome ETF (PBE) ETF
- Exchange
- ARCX
- Inception
- 2005-06-23
- Has Options
- Yes
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-03-23 | 2026-03-27 | $0.0824 | CD |
| 2025-12-22 | 2025-12-26 | $0.4197 | CD |
| 2025-09-22 | 2025-09-26 | $0.2341 | CD |
| 2025-06-23 | 2025-06-27 | $0.1305 | CD |
| 2025-03-24 | 2025-03-28 | $0.0341 | CD |
| 2024-06-24 | 2024-06-28 | $0.0082 | CD |
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc | 5.11% | Equity (US) | — |
| BIIB | Biogen Inc | 5.02% | Equity (US) | — |
| RPRX | Royalty Pharma PLC | 4.98% | Equity (US) | — |
| VRTX | Vertex Pharmaceuticals Inc | 4.95% | Equity (US) | — |
| ALNY | Alnylam Pharmaceuticals Inc | 4.75% | Equity (US) | — |
| REGN | Regeneron Pharmaceuticals Inc | 4.67% | Equity (US) | — |
| UTHR | United Therapeutics Corp | 4.57% | Equity (US) | — |
| GILD | Gilead Sciences Inc | 4.56% | Equity (US) | — |
| LEGN | Legend Biotech Corp | 3.25% | Cash/Money Market | — |
| RGEN | Repligen Corp | 3.06% | Equity (US) | — |
| ILMN | Illumina Inc | 3.03% | Equity (US) | — |
| TECH | Bio-Techne Corp | 2.98% | Equity (US) | — |
| INCY | Incyte Corp | 2.94% | Equity (US) | — |
| PTCT | PTC Therapeutics Inc | 2.92% | Equity (US) | — |
| VCEL | Vericel Corp | 2.92% | Equity (US) | — |
| CDNA | CareDx Inc | 2.90% | Equity (US) | — |
| PTGX | Protagonist Therapeutics Inc | 2.90% | Equity (US) | — |
| VCYT | Veracyte Inc | 2.84% | Equity (US) | — |
| EXEL | Exelixis Inc | 2.83% | Equity (US) | — |
| QGEN | QIAGEN NV | 2.78% | Equity (US) | — |
| BMRN | BioMarin Pharmaceutical Inc | 2.78% | Equity (US) | — |
| NBIX | Neurocrine Biosciences Inc | 2.76% | Equity (US) | — |
| HALO | Halozyme Therapeutics Inc | 2.72% | Equity (US) | — |
| COLL | Collegium Pharmaceutical Inc | 2.69% | Equity (US) | — |
| ACAD | ACADIA Pharmaceuticals Inc | 2.66% | Equity (US) | — |
| BCRX | BioCryst Pharmaceuticals Inc | 2.65% | Equity (US) | — |
| ANAB | AnaptysBio Inc | 2.48% | Equity (US) | — |
| ARDX | Ardelyx Inc | 2.45% | Equity (US) | — |
| SRPT | Sarepta Therapeutics Inc | 2.38% | Equity (US) | — |
| OMER | Omeros Corp | 2.31% | Equity (US) | — |
| AGPXX | Invesco Government & Agency Portfolio | 0.17% | Cash/Money Market | — |
| USD | CASH & EQUIVALENTS | 0.00% | Other | — |
| — | SECURITIES LENDING - BNYM | 0.00% | Cash/Money Market | — |
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | Illumina, Inc. | Illumina, Inc. | 5.68% | $14.9M |
| 2 | Gilead Sciences, Inc. | Gilead Sciences, Inc. | 5.60% | $14.7M |
| 3 | Amgen Inc. | Amgen Inc. | 5.06% | $13.3M |
| 4 | Biogen Inc. | Biogen Inc. | 5.03% | $13.2M |
| 5 | United Therapeutics Corp. | United Therapeutics Corp. | 4.86% | $12.8M |
| 6 | Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. | 4.81% | $12.7M |
| 7 | Incyte Corp. | Incyte Corp. | 4.66% | $12.2M |
| 8 | Amicus Therapeutics, Inc. | Amicus Therapeutics, Inc. | 3.90% | $10.2M |
| 9 | Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals, Inc. | 3.85% | $10.1M |
| 10 | Dynavax Technologies Corp. | Dynavax Technologies Corp. | 3.65% | $9.6M |
| 11 | Qiagen N.V. | Qiagen N.V. | 3.07% | $8.1M |
| 12 | MannKind Corp. | MannKind Corp. | 3.04% | $8.0M |
| 13 | Ionis Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. | 2.84% | $7.5M |
| 14 | Acadia Pharmaceuticals Inc. | Acadia Pharmaceuticals Inc. | 2.84% | $7.5M |
| 15 | Royalty Pharma PLC, Class A | Royalty Pharma PLC | 2.83% | $7.4M |
| 16 | Catalyst Pharmaceuticals, Inc. | Catalyst Pharmaceuticals, Inc. | 2.79% | $7.3M |
| 17 | BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. | 2.75% | $7.2M |
| 18 | Bio-Techne Corp. | Bio-Techne Corp. | 2.72% | $7.2M |
| 19 | Collegium Pharmaceutical, Inc. | Collegium Pharmaceutical, Inc. | 2.72% | $7.1M |
| 20 | Exelixis, Inc. | Exelixis, Inc. | 2.64% | $6.9M |
| 21 | Halozyme Therapeutics, Inc. | Halozyme Therapeutics, Inc. | 2.61% | $6.9M |
| 22 | BioCryst Pharmaceuticals, Inc. | BioCryst Pharmaceuticals, Inc. | 2.60% | $6.8M |
| 23 | Neurocrine Biosciences, Inc. | Neurocrine Biosciences, Inc. | 2.60% | $6.8M |
| 24 | PTC Therapeutics, Inc. | PTC Therapeutics, Inc. | 2.55% | $6.7M |
| 25 | Protagonist Therapeutics, Inc. | Protagonist Therapeutics, Inc. | 2.52% | $6.6M |
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 14.17% | $37.3M | 3 |
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -0.10% | 6 |
| Feb | -1.32% | 6 |
| Mar | -2.15% | 6 |
| Apr | -2.99% | 6 |
| May | +1.32% | 6 |
| Jun | +2.16% | 6 |
| Jul | +3.84% | 5 |
| Aug | +1.45% | 5 |
| Sep | -3.95% | 5 |
| Oct | +1.80% | 5 |
| Nov | +3.23% | 5 |
| Dec | +0.86% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
- IV Rank (30D)
- 12.74
- IV Rank (7D)
- 100
- Avg IV
- 28.4%
- Straddle (30D)
- $5.45
- Straddle (7D)
- $2.38
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.73
- Correlation (SPY)
- 47.6%
- R²
- 0.23
- Ann. Volatility
- 19.0%
- SPY Volatility
- 12.3%
Low volatility - stock moves less than market
Click any bar to view the full quote for that stock.
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|